Author:
Pavankuamr Venkata V.,Vinu C. A.,Mullangi Ramesh,Srinivas Nuggehally R.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology
Reference26 articles.
1. Di Masi J.A. (1994): Risks, regulation, and rewards in new drug development in the United States. Regul. Toxicol. Pharmacol., 19, 228–235.
2. Kuhlmann J. (1997): Drug research: from the idea to the product. Int. J. Clin. Pharmacol. Ther., 35, 541–552.
3. Ings R.M.J. (1990): Interspecies scaling and comparisons in drug development and toxicokinetics. Xenobiotica, 20, 1201–1231.
4. Ritschel W.A., Vachharajani N.N., Johnson R.D., Hussain A.S. (1992): The allometric approach for interspecies scaling of pharmacokinetic parameters. Comp. Biochem. Physiol. C, 103, 249–253.
5. Lin J.H. (1998): Applications and limitations of interspecies scaling andin vitro extrapolation in pharmacokinetics. Drug Metab. Dispos., 12, 1202–1212.
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Prediction of Human Pharmacokinetics of Fomepizole from Preclinical Species Pharmacokinetics Based on Normalizing Time Course Profiles;AAPS PharmSciTech;2019-06-18
2. Multi-Target Drugs Against Metabolic Disorders;Endocrine, Metabolic & Immune Disorders - Drug Targets;2019-06-12
3. Prediction of Human Pharmacokinetics of Bendamustine from Preclinical Species Pharmacokinetics Based on Normalizing Time Course Profiles;Drug Research;2018-07-11
4. The human pharmacokinetics of odanacatib, a novel cathepsin K inhibitor, predicted by interspecies scaling: a retrospective analysis;International Journal of Pharmacokinetics;2017-01
5. Interspecies scaling of excretory amounts using allometry – retrospective analysis with rifapentine, aztreonam, carumonam, pefloxacin, miloxacin, trovafloxacin, doripenem, imipenem, cefozopran, ceftazidime, linezolid for urinary excretion and rifapentine, cabotegravir, and dolutegravir for fecal excretion;Xenobiotica;2015-12-29